5-氯吡啶-3-硼酸频哪醇酯 | 865186-94-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 5-氯吡啶-3-硼酸频哪醇酯
• 中文别名: 5-氯砒啶-3-硼酸频呐醇酯；5-氯吡啶-3-硼酸频哪酯；3-氯-5-(4,4,5,5-四甲基-1,3,2-二氧硼烷)-吡啶；3-氯吡啶-5-硼酸频哪醇酯
• 英文名称: 3-chloro-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine
• CAS: 865186-94-3
• 化学式: C₁₁H₁₅BClNO₂
• mdl: MFCD06798284
• 分子量: 239.51
• InChiKey: WCKBNAJTZUVHPD-UHFFFAOYSA-N

物化性质

• 熔点：
  79-81℃
• 稳定性/保质期：
  按规定使用和贮存的这类物质不会分解，也避免了与氧化物接触。

计算性质

• 辛醇/水分配系数(LogP)：
  3.11
• 重原子数：
  16
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  31.4
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将药品存放在密闭、阴凉、干燥的地方。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
5-Chloropyridine-3-boronic acid, pinacol ester
Product Name:
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
5-Chloropyridine-3-boronic acid, pinacol ester
Ingredient name:
CAS number: 865186-94-3

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C11H15BClNO2
Molecular weight: 239.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-氯吡啶-3-硼酸频哪醇酯 在 copper diacetate 、 三乙胺 、 sodium nitrite 作用下， 以 乙腈 为溶剂， 反应 12.0h， 以0.08 g的产率得到5-硝基-3-氯吡啶
  参考文献：
  名称：

  带有芳基化的芳烃的邻位/对位导向基团的亚硝化

  摘要：

  在本文中，我们报道了荟萃芳烃的-nitration轴承邻/对位用铱催化的C-H硼化反应之后是新开发的铜（II）粗频哪醇的芳基硼酸酯入的催化的变换引导组（多个）以一锅的方式对应的硝基芳烃。该协议允许的合成元-nitrated芳烃是乏味来制备或使用现有的方法需要多步合成。该反应可耐受多种邻位/对位导向基团，例如-F，-Cl，-Br，-CH 3，-Et，-i Pr -OCH 3和-OCF 3。它还提供对π电子缺陷杂环的硝基衍生物（例如吡啶和喹啉衍生物）的区域选择性访问。该方法的应用在复杂分子的后期修饰中以及在以克级制备到FDA批准的药物Nilotinib途中的中间体中得到了证明。最后，我们证明了通过该策略获得的硝基产物也可以通过Baran的胺化方案直接转化为苯胺或受阻胺。

  DOI：

  10.1002/chem.201901633
• 作为产物：
  描述：

  3-氯吡啶 、 联硼酸频那醇酯 在 (1,5-cyclooctadiene)(methoxy)iridium(I) dimer 、 4,4'-二叔丁基-2,2'-二吡啶 作用下， 以 四氢呋喃 为溶剂， 反应 24.03h， 生成 5-氯吡啶-3-硼酸频哪醇酯
  参考文献：
  名称：

  带有芳基化的芳烃的邻位/对位导向基团的亚硝化

  摘要：

  在本文中，我们报道了荟萃芳烃的-nitration轴承邻/对位用铱催化的C-H硼化反应之后是新开发的铜（II）粗频哪醇的芳基硼酸酯入的催化的变换引导组（多个）以一锅的方式对应的硝基芳烃。该协议允许的合成元-nitrated芳烃是乏味来制备或使用现有的方法需要多步合成。该反应可耐受多种邻位/对位导向基团，例如-F，-Cl，-Br，-CH 3，-Et，-i Pr -OCH 3和-OCF 3。它还提供对π电子缺陷杂环的硝基衍生物（例如吡啶和喹啉衍生物）的区域选择性访问。该方法的应用在复杂分子的后期修饰中以及在以克级制备到FDA批准的药物Nilotinib途中的中间体中得到了证明。最后，我们证明了通过该策略获得的硝基产物也可以通过Baran的胺化方案直接转化为苯胺或受阻胺。

  DOI：

  10.1002/chem.201901633

文献信息

• Sterically controlled C–H/C–H homocoupling of arenes <i>via</i> C–H borylation
  作者：Xiaocong Pei、Guan Zhou、Xuejing Li、Yuchen Xu、Resmi C. Panicker、Rajavel Srinivasan

  DOI：10.1039/c9ob00995g

  日期：——

  A mild one-pot protocol for the synthesis of symmetrical biaryls by sequential Ir-catalyzed C-H borylation and Cu-catalyzed homocoupling of arenes is described. The regiochemistry of the biaryl formed is sterically controlled as dictated by the C-H borylation step. The methodology is also successfully extended to heteroarenes. Some of the products obtained by this approach are impossible to obtain

  描述了一种温和的一锅法方案，该方案通过顺序的Ir催化的CH硼酸酯化和Cu催化的芳烃均偶联合成对称的联芳基。所形成的联芳基的区域化学空间上受CH硼酸酯化步骤的控制。该方法还成功地扩展到了杂芳烃。通过这种方法获得的某些产品无法通过Ullmann或Suzuki耦合协议获得。最后，我们显示了一锅序列描述了CH硼化/ Cu催化的均偶联/ Pd催化的Suzuki偶联以获得π扩展的芳烃骨架。
• [EN] METHODS AND COMPOUNDS FOR RESTORING MUTANT p53 FUNCTION<br/>[FR] MÉTHODES ET COMPOSÉS DESTINÉS À LA RESTAURATION D'UNE FONCTION DE MUTANTS DE P53
  申请人：PMV PHARMACEUTICALS INC

  公开号：WO2021262684A1

  公开（公告）日：2021-12-30

  Mutations in oncogenes and tumor suppressors contribute to the development and progression of cancer. The present disclosure describes compounds and methods that restore DNA binding affinity of p53 mutants. The compounds of the present disclosure can bind to mutant p53 and restore the ability of the p53 mutant to bind DNA and activate downstream effectors involved in tumor suppression. The disclosed compounds can be used to reduce the progression of cancers that contain a p53 mutation.

  癌基因和肿瘤抑制基因的突变促成了癌症的发展和进展。本公开披露描述了一种恢复p53突变体DNA结合亲和力的化合物和方法。本公开披露的化合物可以结合突变型p53，并恢复p53突变体结合DNA并激活参与肿瘤抑制的下游效应子的能力。披露的化合物可用于减少含有p53突变的癌症的进展。
• [EN] S PIRO [CHROMAN - 4, 4 ' - IMIDAZOL] ONES AS BETA - SECRETASE INHIBITORS<br/>[FR] SPIRO[CHROMANE-4,4'-IMIDAZOL]ONES EN TANT QU'INHIBITEURS DE BÊTA-SÉCRÉTASE
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011072064A1

  公开（公告）日：2011-06-16

  The invention provides novel spirochroman compounds of Formulas I and II that inhibit β-secretase cleavage of APP and are useful as therapeutic agents for treating neurodegenerative diseases.

  这项发明提供了Formula I和Formula II的新型螺环色苷化合物，可以抑制APP的β-分泌酶裂解，并可用作治疗神经退行性疾病的治疗剂。
• Enzyme‐like Supramolecular Iridium Catalysis Enabling C−H Bond Borylation of Pyridines with <i>meta</i> ‐Selectivity
  作者：Jonathan Trouvé、Paolo Zardi、Shaymaa Al‐Shehimy、Thierry Roisnel、Rafael Gramage‐Doria

  DOI：10.1002/anie.202101997

  日期：2021.8.9

  herein a supramolecular catalyst harnessing Zn⋅⋅⋅N interactions that binds to pyridine-like substrates as tight as it can be found in some enzymes. The distance and spatial geometry between the active site and the substrate binding site is ideal to target unprecedented meta-selective iridium-catalyzed C−H bond borylations with enzymatic Michaelis–Menten kinetics, besides unique substrate selectivity and

  使用底物和催化剂之间的二次相互作用是发现用于原子经济 C-H 键功能化的选择性过渡金属催化剂的有前途的策略。最强大的催化剂是通过反复试验筛选发现的，因为底物和催化剂之间的结合常数低，其中小的立体电子修饰会导致非常不同的反应性。为了规避这些限制并提高这些重要反应中反应性预测的水平，我们在此报告了一种利用 Zn⋅⋅⋅N 相互作用的超分子催化剂，该催化剂与类吡啶底物的结合与在某些酶中发现的一样紧密。
• [EN] BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS<br/>[FR] COMPOSÉS HÉTÉROARYLIQUES BICYCLIQUES ET LEUR UTILISATION COMME INHIBITEURS DE KINASE
  申请人：NOVARTIS AG

  公开号：WO2009010530A1

  公开（公告）日：2009-01-22

  Phosphatidylinositol (PI) 3-kinase inhibitor compounds, their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.

  磷脂酰肌醇（PI）3-激酶抑制剂化合物，其药用盐及其前药；新化合物的组合物，可以单独使用或与至少一种额外治疗剂联合使用，携带药用载体；新化合物的用途，可以单独使用或与至少一种额外治疗剂联合使用，用于预防或治疗由生长因子、蛋白质丝氨酸/苏氨酸激酶和磷脂激酶异常活性所特征化的增殖性疾病。